Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults

Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00522353

Enrollment

Registered

2007-08-29

Start date

2007-01-31

Completion date

2007-08-31

Last updated

2008-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, weight loss, satiety hormones, body composition, appetite ratings

Brief summary

The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.

Detailed description

Obesity is a primary health concern for many western countries as it is linked to several chronic diseases as well as, large health care costs. Although obesity is a multifactorial disease, it is known that levels of satiety hormones including glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to promote weight loss through the production of satiety hormones has been tested previously using rodents. Here it was found that prebiotic supplementation resulted in a decreased energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the gut. This study will address the important question of whether prebiotic fiber supplementation is effective in reducing body weight in overweight or obese human subjects.

Interventions

DIETARY_SUPPLEMENTOligofructose

21 grams per day in distributed over 3 doses per day for 3 months

DIETARY_SUPPLEMENTPlacebo

7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2 * stable body weight in previous 3 months

Exclusion criteria

* Type 1 and Type 2 diabetes * clinically significant cardiovascular abnormalities * liver or pancreas disease * major gastrointestinal surgeries * are pregnant or lactating * exhibit alcohol or drug dependence * on drugs influencing appetite * are following a diet or exercise regime designed for weight loss * have a body mass greater than 350lb * chronic use of antacids or bulk laxatives

Design outcomes

Primary

Measure	Time frame
Body weight	3 months

Secondary

Measure	Time frame
Plasma satiety hormones	3 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026